Cargando…

Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?

Personalized treatment is an attractive strategy that promises increased efficacy with reduced side effects in cancer. The feasibility of such an approach has been greatly boosted by next-generation sequencing (NGS) techniques, which can return detailed information on the genome and on the transcrip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bolli, Niccolo, Genuardi, Elisa, Ziccheddu, Bachisio, Martello, Marina, Oliva, Stefania, Terragna, Carolina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057289/ https://www.ncbi.nlm.nih.gov/pubmed/32181154 http://dx.doi.org/10.3389/fonc.2020.00189

Ejemplares similares

Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma
por: Manzoni, Martina, et al.
Publicado: (2020)

Editorial: Risk factors in multiple myeloma identified before and during treatment: are we ready to personalize treatment?
por: D’Agostino, Mattia, et al.
Publicado: (2023)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
por: Da Vià, Matteo C., et al.
Publicado: (2020)

Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
por: Ziccheddu, Bachisio, et al.
Publicado: (2021)

Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma
por: Manzoni, Martina, et al.
Publicado: (2020)

Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
por: Kim, E. Bridget, et al.
Publicado: (2020)

CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
por: Rodríguez-Otero, Paula, et al.
Publicado: (2020)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
por: Maclachlan, Kylee H., et al.
Publicado: (2021)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Timing the initiation of multiple myeloma
por: Rustad, Even H., et al.
Publicado: (2020)

mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies
por: Rustad, Even H., et al.
Publicado: (2021)

The molecular pathogenesis of multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2020)

Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma
por: Mancuso, Katia, et al.
Publicado: (2023)

Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma
por: Russignan, Anna, et al.
Publicado: (2021)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
por: Bertamini, Luca, et al.
Publicado: (2022)

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR
por: Yao, Qiumei, et al.
Publicado: (2021)

Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma
por: Borsi, Enrica, et al.
Publicado: (2014)

Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma
por: Matera, Antonio, et al.
Publicado: (2022)

Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories
por: Gkoliou, Glykeria, et al.
Publicado: (2023)

DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome
por: Todoerti, Katia, et al.
Publicado: (2021)

Is next-generation radiologist ready for the challenges?
por: Mohan, Chander
Publicado: (2019)

The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
por: Lionetti, Marta, et al.
Publicado: (2021)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma
por: Trudu, Matteo, et al.
Publicado: (2022)

Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
por: Schinke, Carolina, et al.
Publicado: (2023)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Next-generation carrier screening: are we ready?
por: Prior, Thomas W
Publicado: (2014)

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma
por: Steinbach, Mary, et al.
Publicado: (2022)

Melanoma Immunotherapy: Next-Generation Biomarkers
por: Hogan, Sabrina A., et al.
Publicado: (2018)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Intertumoural Heterogeneity and Branch Evolution of Synchronous Multiple Primary Lung Adenocarcinomas by Next-Generation Sequencing Analysis
por: Zhang, Qinleng, et al.
Publicado: (2021)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Author Correction: A practical guide for mutational signature analysis in hematological malignancies
por: Maura, Francesco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_22r0e15807d2jvd1rpghgbedcc